keyword
MENU ▼
Read by QxMD icon Read
search

phase-3 and carcinoma

keyword
https://www.readbyqxmd.com/read/29350403/influence-of-contrast-administration-on-computed-tomography-based-analysis-of-visceral-adipose-and-skeletal-muscle-tissue-in-clear-cell-renal-cell-carcinoma
#1
Michael T Paris, Helena F Furberg, Stacey Petruzella, Oguz Akin, Andreas M Hötker, Marina Mourtzakis
BACKGROUND: Computed tomography (CT) scans are being utilized to examine the influence of skeletal muscle and visceral adipose quantity and quality on health-related outcomes in clinical populations. However, little is known about the influence of contrast administration on these parameters. METHODS: Precontrast, arterial, and 3-minute postcontrast CT images of 45 patients with clear cell renal cell carcinoma were downloaded from The Cancer Imaging Archive and retrospectively analyzed for visceral adipose cross-sectional area (CSA) and density, and muscle CSA and density at the third lumbar vertebrae...
January 19, 2018: JPEN. Journal of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/29348486/phase-i-dose-escalation-study-of-copanlisib-in-combination-with-gemcitabine-or-cisplatin-plus-gemcitabine-in-patients-with-advanced-cancer
#2
R D Kim, S R Alberts, C Peña, I Genvresse, A Ajavon-Hartmann, C Xia, A Kelly, J E Grilley-Olson
BACKGROUND: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant PI3K-α/δ activity that has demonstrated clinical activity and manageable safety when administered as monotherapy in a phase II study. Combination therapy may overcome compensatory signalling that could occur with PI3K pathway inhibition, resulting in enhanced inhibitory activity, and preclinical studies of copanlisib with gemcitabine have demonstrated potent anti-tumour activity in vivo...
January 18, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29346519/final-results-of-a-multi-institutional-phase-ii-trial-of-re-irradiation-with-concurrent-weekly-cisplatin-and-cetuximab-for-recurrent-or-second-primary-squamous-cell-carcinoma-of-the-head-and-neck
#3
M J Awan, L Nedzi, D Wang, V Tumati, B Sumer, X-J Xie, I Smith, J Truelson, R Hughes, L L Myers, P Lavertu, S Wong, M Yao
Background: The optimal regimen of chemotherapy and re-irradiation (re-XRT) for recurrent head and neck squamous cell carcinoma (HNSCC) is controversial. We report the final outcomes of a multi-center Phase II trial evaluating cetuximab and cisplatin-based chemotherapy concurrent with re-XRT for patients with recurrent HNSCC. Methods and Materials: Patients with unresectable recurrent disease or positive margins after salvage surgery arising within a previously irradiated field with KPS≥70 were eligible for this trial...
January 15, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29346507/activity-and-safety-of-afatinib-in-a-window-pre-operative-eortc-study-in-patients-with-squamous-cell-carcinoma-of-the-head-and-neck-scchn
#4
J P Machiels, P Bossi, J Menis, M Lia, C Fortpied, Y Liu, R Lhommel, M Lemort, S Schmitz, S Canevari, L De Cecco, M Guzzo, R Bianchi, P Quattrone, F Crippa, T Duprez, Y Lalami, M Quiriny, N de Saint Aubain, P M Clement, R Coropciuc, E Hauben, L F Licitra
Background: To investigate the activity and safety of afatinib in the pre-operative treatment of squamous cell carcinoma of the head and neck (SCCHN). Patients and methods: This study was an open-label, randomized, multicenter, phase II window of opportunity trial. Treatment-naïve SCCHN patients selected for primary curative surgery were randomized (5:1 ratio) to receive afatinib during 14 days (day -15 until day -1) before surgery (day 0) or no treatment. Tumor biopsies, 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and magnetic resonance imaging (MRI) were performed at diagnosis and just before surgery...
January 15, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29344270/lenvatinib-in-advanced-radioiodine-refractory-thyroid-cancer-a-retrospective-analysis-of-the-swiss-lenvatinib-named-patient-program
#5
Catharina Balmelli, Nikola Railic, Marco Siano, Kristin Feuerlein, Richard Cathomas, Valerie Cristina, Christiane Güthner, Stefan Zimmermann, Sabine Weidner, Miklos Pless, Frank Stenner, Sacha I Rothschild
Purpose: Differentiated thyroid cancer (DTC) accounts for approximately 95% of thyroid carcinomas. In the metastatic RAI-refractory disease, chemotherapy has very limited efficacy and is associated with substantial toxicity. With increasing knowledge of the molecular pathogenesis of DTC, novel targeted therapies have been developed. Lenvatinib is a tyrosine kinase inhibitor (TKI) with promising clinical activity based on the randomized phase III SELECT trial. In Switzerland, a Named Patient Program (NPP) was installed to bridge the time gap to Swissmedic approval...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29344116/knockdown-of-tgif-attenuates-the-proliferation-and-tumorigenicity-of-ec109-cells-and-promotes-cisplatin-induced-apoptosis
#6
Yadong Wang, Teng Pan, Li Li, Haiyu Wang, Jiangmin Li, Ding Zhang, Haiyan Yang
A previous study has reported that frequent amplifications of the TG-interacting factor (TGIF) were observed in esophageal squamous cell carcinoma. The aim of the present study was to investigate the potential role of TGIF in the proliferation and tumorigenicity of the esophageal cancer cell line EC109 and cisplatin-induced apoptosis. Stable TGIF-knockdown EC109 cell line was established by infecting short hairpin RNA (shRNA) lentiviral particles. Soft agar and tumor xenograft assays were applied in nude mice...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29340058/a-multicenter-prospective-phase-ii-study-of-first-line-modified-folfirinox-for-unresectable-advanced-pancreatic-cancer
#7
Kensaku Yoshida, Takuji Iwashita, Shinya Uemura, Akinori Maruta, Mitsuru Okuno, Nobuhiro Ando, Keisuke Iwata, Junji Kawaguchi, Tsuyoshi Mukai, Masahito Shimizu
Background: FOLFIRINOX (FX) has been reported as an effective treatment for unresectable advanced pancreatic cancer. However, FX is associated with a high incidence of adverse events (AEs). A previous phase II study in Japan showed high incidences of hematological AEs, including febrile neutropenia (22.2%). A modified FX regimen (mFX) may decrease the rates of AEs and be more effective than FX by improving the treatment compliance. Aims: To assess the safety and efficacy of first-line mFX for unresectable advanced pancreatic cancer...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29335928/ct-imaging-of-primary-pancreatic-lymphoma-experience-from-three-referral-centres-for-pancreatic-diseases
#8
Enrico Boninsegna, Giulia A Zamboni, Davide Facchinelli, Charikleia Triantopoulou, Sofia Gourtsoyianni, Maria Chiara Ambrosetti, Dino Veneri, Achille Ambrosetti, Roberto Pozzi Mucelli
PURPOSE: To describe CT characteristics of primary pancreatic lymphoma (PPL), a rare disease with features in common with adenocarcinoma. MATERIALS AND METHODS: Fourteen patients were enrolled. CT: unenhanced scan, contrast-enhanced pancreatic and venous phases. Image analysis: tumour location; peri-pancreatic vessel encasement; necrosis; enlarged lymph nodes; fat stranding; enlarged bile duct and pancreatic duct; neoplasm longest dimension, volume and density. RESULTS: Histopathological diagnoses: follicular non-Hodgkin lymphoma (5/14), diffuse large B-cell lymphoma (6/14) and high-grade B-cell lymphoma not otherwise specified (3/14)...
January 15, 2018: Insights Into Imaging
https://www.readbyqxmd.com/read/29333068/nab-paclitaxel-as-second-line-treatment-in-advanced-gastric-cancer-a-multicenter-phase-ii-study-of-the-hellenic-oncology-research-group
#9
Panagiotis Katsaounis, Athanasios Kotsakis, Nikolaos Kentepozidis, Aris Polyzos, Marios Bakogeorgos, Filippos Koinis, Lambros Vamvakas, Nikolaos Vardakis, Kostas Kalbakis, Ioannis Boukovinas, Ioannis I Varthalitis, Efthimios Prinarakis, Vassilis Georgoulias, John Souglakos
Background: This study evaluated the safety and efficacy of nab-paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma. Methods: Thirty-nine pretreated patients [33 with taxane-based regimens (docetaxel, cisplatin, and fluorouracil)] and 6 with combination of fluoropyrimidines plus cisplatin with locally advanced inoperable and metastatic gastric and gastroesophageal junction adenocarcinoma were treated with weekly nab-paclitaxel (150 mg/m2 d1, d8, d15 in cycles of 28 days)...
January 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29330204/pazopanib-exposure-relationship-with-clinical-efficacy-and-safety-in-the-adjuvant-treatment-of-advanced-renal-cell-carcinoma
#10
Cora Sternberg, Frede Donskov, Naomi B Haas, Christian Doehn, Paul Russo, Mohamed A Elmeliegy, Guillaume Baneyx, Hiya Banerjee, Paola Aimone, Robert J Motzer
PURPOSE: PROTECT, a phase III randomized placebo-controlled study, evaluated pazopanib efficacy and safety in the adjuvant RCC setting. The relationship between pazopanib exposure (Ctrough) and efficacy and safety was evaluated. EXPERIMENTAL DESIGN: Evaluable steady-state blood trough concentrations were collected from 311 patients at week 3 or 5 (early Ctrough), and 250 patients at week 16 or 20 (late Ctrough). Pazopanib pharmacokinetic (PK) data was analyzed via a population model approach...
January 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29329568/prospective-longitudinal-quality-of-life-and-survival-outcomes-in-patients-with-advanced-infiltrative-hepatocellular-carcinoma-and-portal-vein-thrombosis-treated-with-yttrium-90-radioembolization
#11
Minzhi Xing, Nima Kokabi, Juan C Camacho, Hyun S Kim
BACKGROUND: To determine the effect of Yttrium-90 (Y90) radioembolization on health-related quality of life (HRQOL) and its effect on overall survival advanced, unresectable infiltrative hepatocellular carcinoma (HCC) patients with concurrent portal vein thrombosis (PVT). METHODS: Consecutive patients with unresectable infiltrative HCC and PVT were recruited. The Short-Form 36 (SF-36) questionnaire was used to assess HRQOL for consecutive patients treated with glass-based Y90 based on a prospective phase II trial...
January 12, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29328466/knockdown-of-immature-colon-carcinoma-transcript%C3%A2-1-induces-suppression-of-proliferation-s-phase-arrest-and-apoptosis-in-leukemia-cells
#12
Guang-Yao Li, Ji-Zhu Liu, Li Zhang, Guo-Zhen Liu, Shuang-Jing Li, Tai-Wu Xiao, Jing-Xia Wang, Le-Xin Wang, Ming Hou
Immature colon carcinoma transcript 1 (ICT1), a human mitochondrial translation release factor, is a ribosome-dependent codon-independent peptidyl-tRNA hydrolase. ICT1-deficiency has been recognized as a cell growth inhibitor of hepatoblastoma and glioblastoma multiforme. To explore the role of ICT1 in human leukemia, 2 short hairpin RNAs (shRNAs) targeting ICT1 sequences were designed in leukemia U937 cells. The successful infection of ICT1 in the U937 cells was observed under a fluorescence microscope and further quantified by western blotting and quantitative real-time PCR (qRT-PCR) analysis...
January 3, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29327075/phase-ii-study-of-sorafenib-combined-with-concurrent-hepatic-arterial-infusion-of-oxaliplatin-5-fluorouracil-and-leucovorin-for-unresectable-hepatocellular-carcinoma-with-major-portal-vein-thrombosis
#13
Min-Ke He, Ru-Hai Zou, Qi-Jiong Li, Zhong-Guo Zhou, Jing-Xian Shen, Yong-Fa Zhang, Zi-Shan Yu, Li Xu, Ming Shi
BACKGROUND: Sorafenib is recommended for the first-line treatment of advanced hepatocellular carcinoma (HCC). However, the median progression-free survival (PFS) of patients with HCC and major portal vein tumor thrombosis treated with sorafenib monotherapy is no more than 3 months. A prospective single-arm phase II study was conducted to determine whether adding hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin to sorafenib could improve on these results...
January 11, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29322827/hypofractionated-volumetric-modulated-arc-therapy-in-ductal-carcinoma-in-situ-toxicity-and-cosmetic-outcome-from-a-prospective-series
#14
Fiorenza De Rose, Antonella Fogliata, Davide Franceschini, Cristina Iftode, Rosalba Torrisi, Giovanna Masci, Andrea Sagona, Corrado Tinterri, Alberto Testori, Wolfgang Gatzemeier, Bethania Fernandes, Daoud Rahal, Luca Cozzi, Armando Santoro, Marta Scorsetti
OBJECTIVE: Hypofractionated radiotherapy in early stage breast cancer is an effective adjuvant treatment, but there is a lack of randomized data for patients with ductal carcinoma in situ (DCIS). Aim of this study is the evaluation of skin toxicity and cosmesis, and early clinical outcome of DCIS patients enrolled in an institutional phase II trial of hypofractionated breast irradiation. METHODS: One hundred thirty-seven DCIS patients were enrolled in the trial...
January 11, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29310387/renal-hybrid-oncocytic-chromophobe-tumor-associated-with-multiple-schwannomas-case-report-and-literature-review
#15
Guanghua Liu, Yatong Li, Zhuoran Li, Jingmin Zhou, Zhen Huo, Zhigang Ji
RATIONALE: Renal hybrid oncocytic/chromophobe tumors (HOCTs) are benign tumors containing a mixture of cells with features of chromophobe renal cell carcinoma (CHRCC) and renal oncocytoma (RO). Sporadic HOCT, which means HOCT occurs in patients without Birt-Hogg-Dubé syndrome (BHDS) or renal oncocytosis, is extremely rare. In this article, we would report a new case of a patient with both sporadic HOCT and multiple Schwannomas, which is even rarer than simplex sporadic HOCT. PATIENT CONCERNS: A 48-year-old female was noted with multiple left-kidney masses and a history of multiple Schwannomas...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29306512/erratum-to-checkmate-025-randomized-phase-3-study-outcomes-by-key-baseline-factors-and-prior-therapy-for-nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma-eur-urol-2017-72-962-71
#16
Bernard Escudier, Padmanee Sharma, David F McDermott, Saby George, Hans J Hammers, Sandhya Srinivas, Scott S Tykodi, Jeffrey A Sosman, Giuseppe Procopio, Elizabeth R Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas C Gauler, Takeshi Ueda, Huanyu Zhao, Ian M Waxman, Robert J Motzer
No abstract text is available yet for this article.
January 3, 2018: European Urology
https://www.readbyqxmd.com/read/29305201/initial-assessment-of-the-efficacy-of-irreversible-electroporation-ire-in-the-focal-treatment-of-localised-renal-cell-carcinoma-rcc-with-delayed-interval-kidney-tumour-resection-irene-trial-an-ablate-and-resect-pilot-study
#17
Johann J Wendler, Maciej Pech, Frank Fischbach, Julian Jürgens, Björn Friebe, Daniel Baumunk, Markus Porsch, Simon Blaschke, Daniel Schindele, Sandra Siedentopf, Jens Ricke, Martin Schostak, Jens Köllermann, Uwe B Liehr
OBJECTIVES: To assess the efficacy of irreversible electroporation (IRE) ablation of pT1a renal-cell carcinoma (RCC) in the first prospective, monocentric Phase 2a pilot ablate-and-resect study (IRENE trial). It has been postulated that focal IRE can bring about complete ablation of soft-tissue tumours with protection of healthy peritumoral tissue and anatomical structures. METHODS: The first seven study patients, with biopsy-proven pT1a RCC (15-39mm) underwent IRE...
January 2, 2018: Urology
https://www.readbyqxmd.com/read/29302704/a-randomized-phase%C3%A2-iii-study-between-sequential-versus-simultaneous-integrated-boost-intensity-modulated-radiation-therapy-in-nasopharyngeal-carcinoma
#18
Chawalit Lertbutsayanukul, Anussara Prayongrat, Danita Kannarunimit, Chakkapong Chakkabat, Buntipa Netsawang, Sarin Kitpanit
PURPOSE: This study was performed to compare the acute and late toxicities between sequential (SEQ) and simultaneous integrated boost (SIB) intensity-modulated radiotherapy (IMRT) in nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: Stage I-IVB NPC patients were randomized to receive SEQ-IMRT or SIB-IMRT. SEQ-IMRT consisted of two plans: 2 Gy × 25 fractions to low-risk planning target volume (PTV) followed by a sequential boost (2 Gy × 10 fractions) to high-risk PTV, while SIB-IMRT treated low- and high-risk PTVs with doses of 56 and 70 Gy in 33 fractions...
January 4, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29302370/atm-signaling-pathway-is-implicated-in-the-smyd3-mediated-proliferation-and-migration-of-gastric-cancer-cells
#19
Lei Wang, Qiu-Tong Wang, Yu-Peng Liu, Qing-Qing Dong, Hai-Jie Hu, Zhi Miao, Shuang Li, Yong Liu, Hao Zhou, Tong-Cun Zhang, Wen-Jian Ma, Xue-Gang Luo
Purpose: We previously found that the histone methyltransferase suppressor of variegation, enhancer of zeste, trithorax and myeloid-nervy-deformed epidermal autoregulatory factor-1 domain-containing protein 3 (SMYD3) is a potential independent predictive factor or prognostic factor for overall survival in gastric cancer patients, but its roles seem to differ from those in other cancers. Therefore, in this study, the detailed functions of SMYD3 in cell proliferation and migration in gastric cancer were examined...
December 2017: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/29301831/efficacy-safety-and-pharmacokinetics-of-axitinib-in-nasopharyngeal-carcinoma-a-preclinical-and-phase-2-correlative-study
#20
Edwin P Hui, Brigette B Y Ma, Herbert Loong, Frankie Mo, Leung Li, Ann D King, Ki Wang, Anil T Ahuja, Charles Ml Chan, Connie Wc Hui, Chi-Hang Wong, Anthony Tc Chan
PURPOSE: We hypothesized that axitinib is active with improved safety profile in nasopharyngeal carcinoma (NPC). EXPERIMENTAL DESIGN: We evaluated axitinib in preclinical models of NPC, and studied its efficacy in a phase 2 clinical trial in recurrent or metastatic NPC patients who progressed after at least one line of prior platinum-based chemotherapy. We excluded patients with local recurrence or vascular invasion. Axitinib was started at 5 mg twice-daily in continuous 4-weeks cycles...
January 4, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
91258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"